CFDA issued the Technical Guide to Conditional Approvals of Launching Drugs Urgently Needed in Clinical Trials onto the Market (Draft for Comment) (“Draft”) on 13 December 2017. The Draft is open for public comments until 14 January 2018. The draft provides that the CFDA may approve the market authorisation for certain drugs before the clinical trial is completed. This is available to drugs used to treat serious or rare diseases with sufficient data to predict the clinical value, or drug used to treat rare disease that have been approved abroad. For the applicable drugs, clinical trials can be conducted after it received market approval.